Nras Exon 2 and 3 Mutation, Tissue

What is NRAS Exon 1 and 2 mutation test?

NRAS Exon 1 and 2 mutation test detects mutations in the NRAS gene, specifically in exons 1 and 2, which code for parts of the NRAS protein involved in cell growth and division. Mutations in NRAS gene can lead to uncontrolled cell signaling, contributing to the development of various cancers such as melanoma, colorectal cancer, leukemia, and thyroid cancer. NRAS Exon 1 and 2 mutation test helps identify whether such mutations are present in a patient’s tumor or blood sample.

Why consider NRAS Exon 1 and 2 mutation test in Idukki?

NRAS Exon 1 and 2 mutation test can be considered

• To guide targeted therapy decisions as certain cancer treatments work better (or worse) depending on NRAS mutation status.

• To help in prognosis and disease characterization as NRAS mutations may indicate how aggressive a cancer is.

• To differentiate between similar cancers with different genetic drivers.

• To monitor disease progression or recurrence in patients with known NRAS-mutant tumors.

Who should get tested for NRAS Exon 1 and 2 mutation test in Idukki

NRAS Exon 1 and 2 mutation test is generally recommended for:

• Patients diagnosed with metastatic or advanced colorectal cancer to determine eligibility for anti-EGFR therapy.

• Individuals with melanoma or hematologic malignancies to identify targeted treatment options.

• Patients whose oncologist suspects a RAS pathway–driven cancer.

• Those being evaluated for molecular profiling of tumors as part of personalized medicine.

It is encoded by the NRAS gene and is a member of the Ras family of proto-oncogenes, meaning that mutations in the gene can contribute to the development of cancer. Mutations in the NRAS gene have been linked to various diseases, including several types of cancer, as well as certain congenital disorders.